Advances in Therapy for Chronic Hepatitis B

Patrick Marcellin

doi:10.1055/s-2002-35698

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2002; 22(s1): 033-036
DOI: 10.1055/s-2002-35698

Advances in Therapy for Chronic Hepatitis B

Patrick Marcellin

Hôpital Beaujon, Clichy, France

Abstract

ABSTRACT

Two agents are currently approved for the treatment of chronic hepatitis B: interferon alfa and lamivudine. Each agent has inherent limitations for use in the treatment of chronic hepatitis B. Interferon alfa is effective in a small number of patients and has serious side effects that limit its tolerability. The efficacy of lamivudine is limited by the emergence of drug-resistant hepatitis B virus (HBV) mutants, restricting its utility as a long-term therapy for chronic hepatitis B. As a result, a large proportion of chronic hepatitis B patients continue to be in need of a safe and efficacious therapy. This article provides an integrated analysis of the safety and efficacy of a new nucleotide analogue, adefovir dipivoxil, based on emerging data from recent studies. The study groups include patients with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative chronic hepatitis B; lamivudine-resistant patients with compensated liver disease; lamivudine-resistant patients coinfected with the human immunodeficiency virus (HIV); and lamivudine-resistant pretransplant and posttransplant patients with decompensated liver disease. Adefovir dipivoxil 10 mg/d demonstrated potent anti-HBV activity consistently across this broad range of patient populations and was well-tolerated. Adefovir dipivoxil's effects include rapid and sustained virological, serological, histological, and biochemical responses, with minimal adverse effects. Significant histological improvement was seen in all patient subgroups at 48 weeks.

KEYWORDS

Chronic hepatitis B - adefovir dipivoxil - antiviral agents - adenine/analogues and derivatives/therapeutic use - drug resistance - hepatitis B virus/drug effects

Full Text

References

REFERENCES

1 World Health Organization. Hepatitis B fact sheet. Geneva, Switzerland:WHO; 2000. Available at: http://www.who.int/ inf-fs/en/fact204.htm (accessed June 04, 2002)
2 Lok A SF, McMahon B J. Chronic hepatitis B. Hepatology . 2001; 34 1225-1241
3 Hoofnagle J H, DiBisceglie A M. The treatment of chronic viral hepatitis. N Engl J Med . 1997; 336 347-356
4 de Man A R, Marcellin P, Habal F. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology . 2000; 32 413-417
5 Marcellin P, Chang T-T, Lim S G. GS-98-437. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. Hepatology . 2001; 34 340A
6 Marcellin P, Goodman Z, Chang T-T. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
7 Hadziyannis S, Tassopoulos N, Heathcote J. GS-98-438. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
8 Liaw Y-F, Leung N WY, Chang T-T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology . 2000; 119 172-180
9 Dienstag J L, Schiff E R, Wright T L. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med . 1999; 341 1256-1263
10 Leung N WY, Lai C-L, Chang T-T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology . 2001; 33 1527-1532
11 Chang T T, Liaw Y F, Guan R. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years (Abst). Antivir Ther . 2000; 5(Suppl 1) 44
12 Peters M, Hann H W, Martin P. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
13 Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology . 1999; 30 1302-1306
14 Benhamou Y, Bochet M, Thibault V. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet . 2001; 358 718-723
15 Benhamou Y, Bochet M, Thibault V. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)
16 Schiff E, Neuhaus P, Tillmann H. Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. Presented at the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst)